Acquisitions (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Acquisitions | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of preliminary purchase price allocation and estimated fair value |
The purchase price allocation for Panoptes is preliminary pending completion of the fair value analysis of acquired assets and liabilities:
(1)Current Assets include cash, receivables, and prepaid expenses of $333,860, $73,368, and $3,635, respectively. |
|||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Proforma disclosure for Panoptes acquisition |
The following table includes the pro forma results for the years ended December 31, 2020 and 2019 of the combined companies as though the Panoptes Acquisition had been completed as of the beginning of the period presented.
|
|||||||||||||||||||||||||||||||||||||||||||||||||